E Fund Management Co. Ltd. Acquires 646 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

E Fund Management Co. Ltd. lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 38.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,339 shares of the biopharmaceutical company’s stock after purchasing an additional 646 shares during the period. E Fund Management Co. Ltd.’s holdings in Regeneron Pharmaceuticals were worth $2,458,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in REGN. Capstone Wealth Management Group LLC raised its stake in Regeneron Pharmaceuticals by 1.8% in the 2nd quarter. Capstone Wealth Management Group LLC now owns 1,828 shares of the biopharmaceutical company’s stock valued at $1,921,000 after acquiring an additional 33 shares during the period. Lmcg Investments LLC raised its stake in Regeneron Pharmaceuticals by 4.7% in the 2nd quarter. Lmcg Investments LLC now owns 4,832 shares of the biopharmaceutical company’s stock valued at $5,079,000 after acquiring an additional 215 shares during the period. Renaissance Technologies LLC raised its stake in Regeneron Pharmaceuticals by 12.0% in the 2nd quarter. Renaissance Technologies LLC now owns 185,162 shares of the biopharmaceutical company’s stock valued at $194,611,000 after acquiring an additional 19,800 shares during the period. Citizens Financial Group Inc. RI raised its stake in Regeneron Pharmaceuticals by 1.1% in the 2nd quarter. Citizens Financial Group Inc. RI now owns 12,130 shares of the biopharmaceutical company’s stock valued at $12,749,000 after acquiring an additional 127 shares during the period. Finally, One Capital Management LLC raised its stake in Regeneron Pharmaceuticals by 6.1% in the 2nd quarter. One Capital Management LLC now owns 11,668 shares of the biopharmaceutical company’s stock valued at $12,263,000 after acquiring an additional 673 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Down 0.5 %

Shares of NASDAQ REGN opened at $1,146.75 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $769.19 and a 12 month high of $1,211.20. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $126.36 billion, a price-to-earnings ratio of 33.88, a PEG ratio of 3.97 and a beta of 0.12. The business has a 50-day moving average of $1,128.09 and a 200-day moving average of $1,028.93.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping the consensus estimate of $8.93 by $2.63. The company had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. Regeneron Pharmaceuticals’s revenue was up 12.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $8.79 earnings per share. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 756 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total value of $802,872.00. Following the completion of the sale, the director now owns 1,382 shares of the company’s stock, valued at $1,467,684. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,137 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the completion of the sale, the executive vice president now owns 12,931 shares of the company’s stock, valued at $13,540,179.41. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Bonnie L. Bassler sold 756 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total value of $802,872.00. Following the completion of the sale, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,467,684. The disclosure for this sale can be found here. Insiders sold a total of 10,026 shares of company stock valued at $11,498,705 over the last quarter. 7.48% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on REGN shares. JPMorgan Chase & Co. boosted their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Truist Financial restated a “buy” rating and issued a $1,200.00 price objective (up from $1,135.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 2nd. Canaccord Genuity Group reaffirmed a “buy” rating and set a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. Guggenheim lifted their target price on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Finally, Piper Sandler lifted their target price on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a report on Friday, August 23rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,111.30.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.